Monday, 23 April 2018 - 10:44
  • it
  • de
  • en
  • fr


Valeant-Takeda’s $10bn deal to sell Salix fails

Valeant renounced to sell its gastrointestinal business unit Salix to Takeda for $10bn. Indeed, talks between the groups reportedly failed, since Valeant is reluctant to provide financial details about Salix. Shares in Valeant instantly lost nearly 9%, which proves that…

Takeda ready to acquire Valeant’s Salix for $10bn

Japan-based Takeda is reported to be in advanced talks with Valeant to acquire Salix Pharmaceuticals. The rumors started circulating yesterday night, when Valeant’s management confirmed ongoing talks about Salix. Valeant’s shares soon rose by almost 30%, even though selling Salix…